What Researchers Did
Researchers reviewed current approaches to managing zygomycosis, an invasive fungal infection, in patients with haematological malignancies.
What They Found
They found that liposomal amphotericin B has become the therapeutic agent of choice, while posaconazole demonstrated promising results in salvage therapy. Adjuvant iron chelation with deferasirox also showed promising outcomes, although clinical experience is still limited.
What This Means for Canadian Patients
Canadian patients with haematological malignancies suffering from zygomycosis may benefit from early diagnosis, aggressive antifungal therapy, and surgical debridement. Effective treatment options include liposomal amphotericin B and posaconazole, with deferasirox as a potential adjuvant therapy.
Canadian Relevance
This study does not have a direct Canadian connection.
Study Limitations
The discussed management approaches are primarily founded on clinical experience rather than comparative studies.